Ewing's sarcoma
ICD-10 C40 · ICD-11 2B52

Treatment of Ewing's Sarcoma in Cutaneous or Subcutaneous Presentation

Clinical scenario

This protocol addresses Ewing's sarcoma arising in the cutaneous or subcutaneous tissues — a distinct sub-population within the broader Ewing sarcoma family.

Retrospective evidence indicates that cutaneous and subcutaneous Ewing sarcoma carries a more favourable prognosis compared with other localised soft tissue Ewing sarcoma. Because of this, the number of treatment cycles requires individual discussion at a multidisciplinary level and with the patient.
Treatment approach — partial overview

For appropriately selected patients experiencing relapse after a sustained disease-free period, a consolidation strategy involving intensive chemotherapy may be considered — provided complete remission has been achieved. Full eligibility criteria, sequencing, and regimen details are in the complete protocol…

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1016/j.annonc.2021.08.1995

There is retrospective evidence suggesting that cutaneous and subcutaneous ES have a better prognosis compared with other localised soft tissue ES.

Given their favourable prognosis, the number of cycles in cutaneous and subcutaneous ES is to be discussed case by case, at a multidisciplinary level and with the patient [V, C].

For selected patients with a long disease-free interval of ≥2 years achieving a complete remission through medical therapy and/or surgery, consolidation with high-dose ChT may be considered [V, C].

View source ↗